98%
921
2 minutes
20
Agrocybe aegerita polysaccharides (AAP), known for their diverse pharmacological properties, have yet to be fully understood in terms of their structure evaluation, effects and mechanisms on tumor-associated macrophages in colorectal cancer. Agrocybe aegerita polysaccharides were extracted using hot water and subsequently purified. Their structure was elucidated through methylation and nuclear magnetic resonance analyses. The impact of AAP-0.2A on macrophage polarization was assessed using flow cytometry, immunofluorescence, and ELISA. Furthermore, transcriptomics, molecular docking and western blot were employed to investigate the specific mechanisms by which AAP-0.2A influence macrophage polarization. Conditioned media were applied to CT26 cells to evaluate the effects on the proliferation and apoptosis of colorectal cancer cells. These findings demonstrate that AAP-0.2A are neutral fuco-galactoglucans that increased M1 phenotype markers of CD86, CCR7, IFN-γ while decreased M2 phenotype markers of CD206, Arg1 and IL-10. They enhance M1 macrophage polarization by activating the NF-κB/NLRP3 and HIF1A/P53 pathways. Further studies have shown that AAP-0.2A inhibit the proliferation and induce apoptosis of colorectal cancer cells, counteracting the effects of IL-4-conditioned media. These results suggested that AAP-0.2A repolarized macrophages from M2 to M1 phenotype through activating NF-κB/NLRP3 and HIF-1α/p53 pathways to inhibit the proliferation and induce apoptosis of colorectal cancer cells.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijbiomac.2025.146559 | DOI Listing |
Front Immunol
September 2025
Guangxi Key Laboratory of AIDS Prevention and Treatment & School of Public Health, Guangxi Medical University, Nanning, Guangxi, China.
Background: People living with HIV(PLWH) are a high-risk population for cancer. We conducted a pioneering study on the gut microbiota of PLWH with various types of cancer, revealing key microbiota.
Methods: We collected stool samples from 54 PLWH who have cancer (PLWH-C), including Kaposi's sarcoma (KS, n=7), lymphoma (L, n=22), lung cancer (LC, n=12), and colorectal cancer (CRC, n=13), 55 PLWH who do not have cancer (PLWH-NC), and 49 people living without HIV (Ctrl).
Front Oncol
August 2025
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Objective: The retrieval of 12 lymph nodes (LNs) remains a crucial criterion for accurate staging and prognosis evaluation in rectal cancer (RC). However, some patients fail to meet this threshold after surgery. This study developed a nomogram model based on clinical variables to predict the probability of retrieving 12 LNs postoperatively.
View Article and Find Full Text PDFFront Oncol
August 2025
Department of Surgery, Hebei Medical University, Shijiazhuang, Hebei, China.
Background: Tumor deposit (TD) is an independent risk factor associated with recurrence or metastasis for patients with colorectal cancer (CRC). The scenario in which both TD and lymph node metastasis (LNM) are positive is not clearly illustrated by the current TNM staging system. Simply treating one TD as one or two LNMs by a weighting factor is inappropriate.
View Article and Find Full Text PDFFront Oncol
August 2025
Department of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, United States.
Introduction: Metastatic colorectal cancer (mCRC) exhibits significant heterogeneity in molecular profiles, influencing treatment response and patient outcomes. Mutations in v-raf murine sarcoma viral oncogene homolog B1 () and rat sarcoma () family genes are commonly observed in mCRC. Though originally thought to be mutually exclusive, recent data have shown that patients may present with concomitant and mutations, posing unique challenges and implications for clinical management.
View Article and Find Full Text PDFPrev Oncol Epidemiol
May 2025
Implenomics, Dover, DE, USA.
Introduction: We identified potential approaches to address barriers to colorectal cancer (CRC) screening in rural communities of award recipients from the Centers for Disease Control and Prevention's Colorectal Cancer Control Program (CRCCP).
Methods: Nine program managers and directors discussed approaches to address barriers to CRC screening. The programs served areas with rural communities and tribal reservations.